Georgia Life Sciences: Anti-Racism Statement and Commitment to Diversity, Equity, and Inclusion

At Georgia Life Sciences, we believe inclusive excellence is fundamental to advancing innovation, improving health outcomes, and strengthening the life sciences economy. Our mission—to expand access to breakthrough technologies and enhance the well-being of people worldwide—can only be realized when every voice is heard, valued, and respected.



We denounce all forms of racism, discrimination, and hate. Our organization stands firmly against actions or rhetoric that seek to divide based on race, ethnicity, religion, gender, or any other identity. These principles are non-negotiable and remain central to our work.

We know that diverse perspectives fuel scientific discovery, business innovation, and workforce resilience. As a statewide, nonpartisan convener, Georgia Life Sciences is committed to fostering a life sciences ecosystem that reflects the diversity of the communities we serve.

This commitment includes:


  • Continual Learning and Accountability: We are committed to listening, adapting, and evolving our practices to ensure fairness, access, and opportunity across our programs and partnerships.
  • Expanding Access: We work intentionally to ensure underrepresented voices are included in shaping Georgia’s life sciences future—from workforce development to innovation to policy.
  • Collaborative Leadership: We invite our members, partners, and stakeholders to join us in building a more inclusive, equitable, and impactful life sciences community—together.


Inclusive excellence is not a separate initiative—it is a foundational value that informs everything we do.

September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS